Figure 1: Structure and DPP-IV inhibition of CMD-05.
From: CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies

The structures of vildagliptin and CMD-05 (A). The inhibitory effect of CMD-05 on recombinant human DPP-IV (B). Vildagliptin and CMD-05 inhibited DPP-IV activity with an IC50 of approximately 3.5 nM and 12 nM, respectively. Data are expressed as the mean ± SD of three determinations.